The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Future directions in T-cell lymphoma
Matko Kalac, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses future directions in T-cell lymphoma, highlighting a study investigating the use of romidepsin and azacitidine versus investigator’s choice, and further commenting on the potential use of CAR-T therapy and other novel agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research: Johnson & Johnson
